Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 4, 2009

View Archived Issues

New naturally derived antidiabetic compound preserves beta-cell function in preclinical studies

Beta-secretase inhibitors for the treatment of Alzheimer's disease disclosed by Boehringer Ingelheim

L-2286 attenuates myocardial hypertrophy in spontaneously hypertensive rats

AZD-0837 effects on fibrin D-dimer levels and pharmacokinetics correlated in phase II study

Novel angiotensin II antagonists described by Merck & Co. as antihypertensives

Roche claims c-Met inhibitors for the treatment of cancer and other conditions

Cangrelor prevents binding of clopidogrel and prasugrel active metabolites to P2Y12

Wyeth describes novel 5-HT2C receptor agonists with atypical antipsychotic activity

Gold nanoparticles developed for the diagnosis of lung cancer in breath samples

BioMS Medical and Lilly terminate license and collaboration agreement for dirucotide in MS

FDA recommends accelerated approval for Allos Therapeutics' Folotyn in PTCL

Amura Therapeutics reports results from rheumatoid arthritis study

U.S. bankruptcy court approves Cornerstone Therapeutics' acquisition of Oscient's Factive

FDA accepts for review Takeda's sNDA for Velcade in previously untreated multiple myeloma

FDA extends review period for Endo's testosterone undecanoate for hypogonadism

Alla Chem presents 5-HT6 receptor antagonists for the treatment of cognition disorders

Pharming submits new MAA to EMEA for Rhucin for acute hereditary angioedema attacks

Calcium channel blockers claimed by Cosunter as antihypertensives

Peplin to be acquired by Leo Pharma for USD 287.5 million in cash

Delta opioid receptor agonist ADL-5747 advances to phase I safety trial based on in vivo activity

Genfit and Bicoll report preliminary results from OLNORME research project

Diamyd Medical reports 4-year follow-up data from phase II study of Diamyd

MabThera approved in Europe for previously treated chronic lymphocytic leukemia

FDA approves once-daily Intuniv for ADHD

Santhera initiates phase III idebenone trial in Duchenne muscular dystrophy

Merck & Co. launches tafluprost in the U.K. and Spain for glaucoma and ocular hypertension

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...